T3	ethinicity 72 78	Korean
T4	condition 609 629	AI-induced bone loss
T6	total-participants 823 825	98
T8	control 1007 1014	placebo
T12	outcome 1176 1201	increase in C-telopeptide
T1	intervention 23 68	alendronate and calcitriol agent (MaxmarvilÂ®)
T2	eligibility 79 154	postmenopausal women with early breast cancer receiving aromatase inhibitor
T5	outcome 1120 1130	lumbar BMD
T7	outcome 1202 1216	after 24 weeks
T9	iv-cont-mean 1302 1306	35.2
T11	iv-cont-sd 1309 1314	17.5%
T13	cv-cont-mean 1319 1324	109.8
T14	cv-cont-sd 1327 1332	28.6%
T15	outcome 1090 1100	At week 24
